Amalgamated Bank’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $720K | Sell |
15,479
-922
| -6% | -$44.3K | 0.01% | 1245 |
|
|
2026
Q1 | $848K | Sell |
16,401
-157
| -0.9% | -$8K | 0.01% | 1133 |
|
|
2025
Q4 | $823K | Buy |
16,558
+528
| +3% | +$25.7K | 0.01% | 1149 |
|
|
2025
Q3 | $766K | Buy |
16,030
+313
| +2% | +$12.6K | 0.01% | 1155 |
|
|
2025
Q2 | $495K | Buy |
15,717
+152
| +1% | +$4.87K | ﹤0.01% | 1287 |
|
|
2025
Q1 | $510K | Sell |
15,565
-554
| -3% | -$19.6K | ﹤0.01% | 1246 |
|
|
2024
Q4 | $583K | Buy |
16,119
+3
| +0% | +$106 | ﹤0.01% | 1249 |
|
|
2024
Q3 | $502K | Sell |
16,116
-260
| -2% | -$8.12K | ﹤0.01% | 1298 |
|
|
2024
Q2 | $438K | Sell |
16,376
-441
| -3% | -$12.8K | ﹤0.01% | 1350 |
|
|
2024
Q1 | $574K | Sell |
16,817
-6,059
| -26% | -$180K | ﹤0.01% | 1260 |
|
|
2023
Q4 | $662K | Sell |
22,876
-505
| -2% | -$13.4K | 0.01% | 1327 |
|
|
2023
Q3 | $645K | Sell |
23,381
-673
| -3% | -$20.5K | 0.01% | 1295 |
|
|
2023
Q2 | $723K | Buy |
24,054
+1,822
| +8% | +$63.8K | 0.01% | 1269 |
|
|
2023
Q1 | $805K | Sell |
22,232
-1,821
| -8% | -$70K | 0.01% | 1196 |
|
|
2022
Q4 | $858K | Buy |
24,053
+416
| +2% | +$14.5K | 0.01% | 1210 |
|
|
2022
Q3 | $800K | Buy |
23,637
+188
| +0.8% | +$6.12K | 0.01% | 1198 |
|
|
2022
Q2 | $678K | Buy |
23,449
+70
| +0.3% | +$2K | 0.01% | 1318 |
|
|
2022
Q1 | $756K | Sell |
23,379
-1,167
| -5% | -$35.8K | 0.01% | 1348 |
|
|
2021
Q4 | $716K | Sell |
24,546
-593
| -2% | -$18K | 0.01% | 1398 |
|
|
2021
Q3 | $670K | Sell |
25,139
-475
| -2% | -$12.7K | 0.01% | 1441 |
|
|
2021
Q2 | $789K | Buy |
+25,614
| New | +$785K | 0.01% | 1400 |
|
|
2020
Q1 | – | Sell |
-9,379
| Closed | -$222K | – | 1769 |
|
|
2019
Q4 | $222K | Buy |
9,379
+117
| +1% | +$2.84K | ﹤0.01% | 1589 |
|
|
2019
Q3 | $255K | Sell |
9,262
-94
| -1% | -$2.79K | 0.01% | 1418 |
|
|
2019
Q2 | $310K | Buy |
9,356
+1,458
| +18% | +$50K | 0.01% | 1333 |
|
|
2019
Q1 | $277K | Buy |
7,898
+178
| +2% | +$6.62K | 0.01% | 1314 |
|
|
2018
Q4 | $256K | Buy |
+7,720
| New | +$332K | 0.01% | 1269 |
|
|
2018
Q3 | – | Sell |
-8,007
| Closed | -$479K | – | 1607 |
|
|
2018
Q2 | $479K | Buy |
8,007
+1,028
| +15% | +$53.3K | 0.01% | 1050 |
|
|
2018
Q1 | $320K | Sell |
6,979
-103
| -1% | -$4.3K | 0.01% | 1177 |
|
|
2017
Q4 | $282K | Buy |
7,082
+543
| +8% | +$21.5K | 0.01% | 1302 |
|
|
2017
Q3 | $262K | Sell |
6,539
-39
| -0.6% | -$1.69K | 0.01% | 1301 |
|
|
2017
Q2 | $284K | Buy |
+6,578
| New | +$234K | 0.01% | 1227 |
|
Other funds holding SUPN
SIMG
RHJA
GT
Amalgamated Bank's SUPN Position: Q2 2026 in Review
Amalgamated Bank reduced its Supernus Pharmaceuticals (SUPN) stake by 5.6% in Q2 2026, selling an estimated $44.3K and leaving 15,479 shares worth $720K. The position accounts for 0.01% of the portfolio, ranked #1245.
Amalgamated Bank first reported a position in SUPN in Q2 2017 and has held it in 31 quarters since. The position peaked at $858K in Q4 2022. 139 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.
- Amalgamated Bank held 15,479 shares of Supernus Pharmaceuticals worth $720K as of Q2 2026.
- Amalgamated Bank sold 922 Supernus Pharmaceuticals shares in Q2 2026, an estimated $44.3K.
- Supernus Pharmaceuticals made up 0.01% of Amalgamated Bank's portfolio in Q2 2026, its #1245 holding.
- Amalgamated Bank first reported a position in Supernus Pharmaceuticals in Q2 2017 and has held it in 31 quarters since.
- Amalgamated Bank's Supernus Pharmaceuticals position peaked at $858K in Q4 2022.
- 139 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.
Based on Amalgamated Bank's 13F filing for Q2 2026, filed 23 Jul 2026.